Search Results

You are looking at 271 - 280 of 2,880 items for :

  • Refine by Access: All x
Clear All
Full access

NCCN Framework for Resource Stratification: A Framework for Providing and Improving Global Quality Oncology Care

Robert W. Carlson, Jillian L. Scavone, Wui-Jin Koh, Joan S. McClure, Benjamin E. Greer, Rashmi Kumar, Nicole R. McMillian, and Benjamin O. Anderson

mature and organized health care infrastructure. They make no recommendations about how resource expenditures should be prioritized to achieve the greatest clinical benefit and outcome. Most of the currently available clinical practice guidelines, such as

Full access

HSR20-102: Quality Outcomes in Colon Cancer

Michelle Moskal and Neeharika S. Makani

Full access

A Systematic Review of Clinical Decision Support Systems for Clinical Oncology Practice

Pamala A. Pawloski, Gabriel A. Brooks, Matthew E. Nielsen, and Barbara A. Olson-Bullis

-based standardization of cancer care, improving care delivery and patient outcomes. CDS tools have been incorporated across the patient care spectrum, encompassing prevention, diagnosis, and clinical monitoring. Common roles for CDS include computerized physician order

Full access

HSR21-070: Feasibility of Tracking Digital Activity, Sleep, and Patient-Reported Outcomes (PROs) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Undergoing an In-Class Transition From Parenteral Bortezomib-Based Therapy to Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) in the Ongoing Community-Based United States (US) MM-6 Study (NCT03173092)

Kirsten Stuber, Habte A. Yimer, Karin Choquette, Sudhir Manda, Jennifer Clayton, Saulius Girnius, Joshua Richter, Presley Whidden, Kimberly Bogard, Dasha Cherepanov, and Stephen J. Noga

(QoL) and improving outcomes. We evaluated the feasibility of digital actigraphy (monitoring activity/rest) and electronic PRO (ePRO) data collection using wearable and mobile devices in an older MM pt population (median age 73 years). Methods

Full access

Plenary Session—The Patient Journey: Cancer Survivor Care

Presented by: Shannon M. Ansbaugh, Gary Deng, Rev. George F. Handzo, and Karen L. Syrjala

Moderated by: Jessica R. Bauman

without cancer. Dr. Syrjala noted that some of these outcomes, such as symptoms of post-traumatic stress (different from a full diagnosis of PTSD) can persist for 10 to 15 years after diagnosis. Figure 1. Mental health outcomes in post

Full access

Multidisciplinary Management of Pancreatic Cancer

Margaret A. Tempero

essentially be summarized as a half dozen clinical trials evaluating gemcitabine and 5-fluorouracil (FU), with and without radiation. Outcomes from these trials were largely similar, with median OS hovering around 22 months and 25% to 30% of patients dying of

Full access

Benefits of High-Volume Medical Oncology Care for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis

Julie Hallet, Laura Davis, Alyson Mahar, Michail Mavros, Kaitlyn Beyfuss, Ying Liu, Calvin H.L. Law, Craig Earle, and Natalie Coburn

Background As medical and surgical therapies advance, cancer care has become increasingly complex. Clinical volume is an important construct in the delivery of specialized care, and provider volume has been associated with improved outcomes of

Full access

NCCN Task Force Report: Positron Emission Tomography (PET)/Computed Tomography (CT) Scanning in Cancer

Donald A. Podoloff, Ranjana H. Advani, Craig Allred, Al B. Benson III, Elizabeth Brown, Harold J. Burstein, Robert W. Carlson, R. Edward Coleman, Myron S. Czuczman, Dominique Delbeke, Stephen B. Edge, David S. Ettinger, Frederic W. Grannis Jr., Bruce E. Hillner, John M. Hoffman, Krystyna Kiel, Ritsuko Komaki, Steven M. Larson, David A. Mankoff, Kenneth E. Rosenzweig, John M. Skibber, Joachim Yahalom, JQ Michael Yu, and Andrew D. Zelenetz

any prior knowledge of the results of other studies is essential. Finally, assessing how the results of the PET scan impact patient management and improve health outcomes is important. Health outcomes include not only survival but also quality of life

Full access

Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI

Thomas Melchardt, Katharina Troppan, Lukas Weiss, Clemens Hufnagl, Daniel Neureiter, Wolfgang Tränkenschuh, Konstantin Schlick, Florian Huemer, Alexander Deutsch, Peter Neumeister, Richard Greil, Martin Pichler, and Alexander Egle

with an independent and reproducible influence on the clinical outcome may further improve the NCCN-IPI. Patients and Methods This retrospective analysis was approved by the Ethics Committee of the provincial government of Salzburg, Austria (415

Full access

Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients With Cancer

Gerald A. Soff

was given for at least 6 months and up to 12 months. 3 For the primary outcome measure—a composite of recurrent VTE or major bleeding during the 12 months after randomization—edoxaban proved to be noninferior to LMWH ( Figure 2 ). “The hazard ratios